Last reviewed · How we verify

Tri-luma — Competitive Intelligence Brief

Tri-luma (Tri-luma) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical depigmenting agent combination. Area: Dermatology.

marketed Topical depigmenting agent combination Tyrosinase; retinoic acid receptor; glucocorticoid receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Tri-luma (Tri-luma) — Hexsel Dermatology Clinic. Tri-Luma is a topical combination that inhibits melanin production and reduces hyperpigmentation through multiple mechanisms including tyrosinase inhibition and corticosteroid activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tri-luma TARGET Tri-luma Hexsel Dermatology Clinic marketed Topical depigmenting agent combination Tyrosinase; retinoic acid receptor; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical depigmenting agent combination class)

  1. Hexsel Dermatology Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tri-luma — Competitive Intelligence Brief. https://druglandscape.com/ci/tri-luma. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: